UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

X QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2019

OR

TRANSITION REPORT PURSUANT TO SECTION 13

OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______ to _______

COMMISSION FILE NUMBER 1-3619

----

PFIZER INC.

(Exact name of registrant as specified in its charter)

DELAWARE

(State of Incorporation)

13-5315170

(I.R.S. Employer Identification No.)

235 East 42nd Street, New York, New York 10017

(Address of principal executive offices) (zip code)

(212) 733-2323

(Registrant s telephone number)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

YES X

NO ___

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T ( 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

YES X

NO ___

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act:

Large Accelerated filer X Accelerated filer ___ Non-accelerated filer ___ Smaller reporting company ___ Emerging growth company ___

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ___

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

YES ____

NO X

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $.05 par value

PFE

New York Stock Exchange

0.000% Notes due 2020

PFE20A

New York Stock Exchange

0.250% Notes due 2022

PFE22

New York Stock Exchange

1.000% Notes due 2027

PFE27

New York Stock Exchange

At May 6, 2019, 5,559,929,190 shares of the issuer s voting common stock were outstanding.

Table of Contents

PART I. FINANCIAL INFORMATION

Page

Item 1.

Financial Statements

Condensed Consolidated Statements of Income for the three months ended March 31, 2019 and April 1, 2018

Condensed Consolidated Statements of Comprehensive Income for the three months ended March 31, 2019 and April 1, 2018

Condensed Consolidated Balance Sheets as of March 31, 2019 and December 31, 2018

Condensed Consolidated Statements of Equity for the three months ended March 31, 2019 and April 1, 2018

Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2019 and April 1, 2018

Notes to Condensed Consolidated Financial Statements

10

Review Report of Independent Registered Public Accounting Firm

43

Item 2.

Management s Discussion and Analysis of Financial Condition and Results of Operations

44

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

93

Item 4.

Controls and Procedures

93

PART II. OTHER INFORMATION

Item 1.

Legal Proceedings

94

Item 1A.

Risk Factors

94

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

95

Item 3.

Defaults Upon Senior Securities

95

Item 4.

Mine Safety Disclosures

95

Item 5.

Other Information

95

Item 6.

Exhibits

96

Signature

97

GLOSSARY OF DEFINED TERMS

Unless the context requires otherwise, references to Pfizer, the Company, we, us or our in this Quarterly Report on Form 10-Q (defined below) refer to Pfizer Inc. and its subsidiaries. We also have used several other terms in this Quarterly Report on Form 10-Q, most of which are explained or defined below:

2018 Financial Report

Financial Report for the fiscal year ended December 31, 2018, which was filed as Exhibit 13 to the Annual Report on Form 10-K for the fiscal year ended December 31, 2018

2018 Form 10-K

Annual Report on Form 10-K for the fiscal year ended December 31, 2018

ACA (Also referred to as U.S. Healthcare Legislation)

U.S. Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act

ACIP

Advisory Committee on Immunization Practices

ALK

anaplastic lymphoma kinase

Alliance revenues

Revenues from alliance agreements under which we co-promote products discovered or developed by other companies or us

Allogene

Allogene Therapeutics, Inc.

Anacor

Anacor Pharmaceuticals, Inc.

AOCI

Accumulated Other Comprehensive Income

Astellas

Astellas Pharma Inc., Astellas US LLC and Astellas Pharma US, Inc.

Bamboo

Bamboo Therapeutics, Inc.

Biopharma

Pfizer Biopharmaceuticals Group

BMS

Bristol-Myers Squibb Company

BRCA

BReast CAncer susceptibility gene

CAR T

chimeric antigen receptor T cell

CDC

U.S. Centers for Disease Control and Prevention

cGMP

current Good Manufacturing Practices

Citibank

Citibank, N.A.

Developed Markets

U.S., Western Europe, Japan, Canada, South Korea, Australia, Scandinavian countries, Finland and

New Zealand

EEA

European Economic Area

EGFR

epidermal growth factor receptor

EH

Essential Health

EMA

European Medicines Agency

Emerging Markets

Includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea),

Latin America, Eastern Europe, the Middle East, Africa, Central Europe and Turkey

EPS

earnings per share

EU

European Union

Exchange Act

Securities Exchange Act of 1934, as amended

FASB

Financial Accounting Standards Board

FDA

U.S. Food and Drug Administration

GAAP

Generally Accepted Accounting Principles

GIST

gastrointestinal stromal tumors

GPD

Global Product Development organization

GSK

GlaxoSmithKline plc

GS&Co.

Goldman, Sachs & Co. LLC

HER2-

human epidermal growth factor receptor 2-negative

hGH-CTP

human growth hormone

HIS

Hospira Infusion Systems

Hisun Pfizer

Hisun Pfizer Pharmaceuticals Company Limited

Hospira

Hospira, Inc.

HR+

hormone receptor-positive

ICU Medical

ICU Medical, Inc.

IH

Innovative Health

IPR&D

in-process research and development

IRS

U.S. Internal Revenue Service

IV

intravenous

Janssen

Janssen Biotech Inc.

J&J

Johnson & Johnson

King

King Pharmaceuticals LLC (formerly King Pharmaceuticals, Inc.)

LDL

low density lipoprotein

LEP

Legacy Established Products

LIBOR

London Interbank Offered Rate

Lilly

Eli Lilly & Company

LOE

loss of exclusivity

MCC

Merkel cell carcinoma

MCO

managed care organization

MD&A

Management s Discussion and Analysis of Financial Condition and Results of Operations

Medivation

Medivation LLC (formerly Medivation, Inc.)

Merck

Merck & Co., Inc.

Meridian

Meridian Medical Technologies, Inc.

Moody s

Moody s Investors Service

NDA

new drug application

NSCLC

non-small cell lung cancer

NYSE

New York Stock Exchange

OPKO

OPKO Health, Inc.

OTC

over-the-counter

PARP

poly ADP ribose polymerase

PBM

pharmacy benefit manager

Pharmacia

Pharmacia Corporation

PP&E

property, plant & equipment

PsA

psoriatic arthritis

Quarterly Report on Form 10-Q

Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2019

RA

rheumatoid arthritis

RCC

renal cell carcinoma

R&D

research and development

ROU

right of use

Sandoz

Sandoz, Inc., a division of Novartis AG

SBS

short bowel syndrome

SEC

U.S. Securities and Exchange Commission

SFJ

SFJ Pharmaceuticals Group

Shire

Shire International GmbH

SI&A

selling, informational and administrative

SIP

sterile injectable pharmaceuticals

S&P

Standard and Poor s

Tax Cuts and Jobs Act or TCJA

legislation commonly referred to as the U.S. Tax Cuts and Jobs Act of 2017

Therachon

Therachon Holding AG

UC

ulcerative colitis

U.K.

United Kingdom

U.S.

United States

ViiV

ViiV Healthcare Limited

WRDM

Worldwide Research, Development and Medical

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(UNAUDITED)

Three Months Ended

(MILLIONS, EXCEPT PER COMMON SHARE DATA)

March 31,

2019

April 1,

2018

Revenues

13,118

12,906

Costs and expenses:

Cost of sales(a)

2,433

2,563

Selling, informational and administrative expenses(a)

3,339

3,412

Research and development expenses(a)

1,703

1,743

Amortization of intangible assets

1,183

1,196

Restructuring charges and certain acquisition-related costs

46

43

Other (income)/deductions net

92

(178

Income from continuing operations before provision for taxes on income

4,323

4,127

Provision for taxes on income

433

556

Income from continuing operations

3,889

3,571

Discontinued operations net of tax

(1

Net income before allocation to noncontrolling interests

3,889

3,570

Less: Net income attributable to noncontrolling interests

Net income attributable to Pfizer Inc.

3,884

3,561

Earnings per common share basic:

Income from continuing operations attributable to Pfizer Inc. common shareholders

0.69

0.60

Discontinued operations net of tax

Net income attributable to Pfizer Inc. common shareholders

0.69

0.60

Earnings per common share diluted:

Income from continuing operations attributable to Pfizer Inc. common shareholders

0.68

0.59

Discontinued operations net of tax

Net income attributable to Pfizer Inc. common shareholders

0.68

0.59

Weighted-average shares basic

5,635

5,957

Weighted-average shares diluted

5,750

6,057

(a)

Excludes amortization of intangible assets, except as disclosed in Note 9A. Identifiable Intangible Assets and Goodwill: Identifiable Intangible Assets.

Amounts may not add due to rounding.

See Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(UNAUDITED)

Three Months Ended

(MILLIONS OF DOLLARS)

March 31,

2019

April 1,

2018

Net income before allocation to noncontrolling interests

3,889

3,570

Foreign currency translation adjustments, net

324

758

Reclassification adjustments

15

326

773

Unrealized holding gains/(losses) on derivative financial instruments, net

267

(114

Reclassification adjustments for (gains)/losses included in net income(a)

(263

44

(69

Unrealized holding gains on available-for-sale securities, net

40

160

Reclassification adjustments for (gains)/losses included in net income(a)

11

(174

Reclassification adjustments for unrealized gains included in Retained earnings(b)

(462

51

(476

Benefit plans: actuarial gains, net

163

Reclassification adjustments related to amortization

60

62

Reclassification adjustments related to settlements, net

37

Other

(23

(86

37

175

Reclassification adjustments related to amortization of prior service costs and other, net

(46

(46

Reclassification adjustments related to curtailments of prior service costs and other, net

(7

Other

(46

(51

Other comprehensive income, before tax

372

352

Tax provision on other comprehensive income

25

432

Other comprehensive income/(loss) before allocation to noncontrolling interests

348

(80

Comprehensive income before allocation to noncontrolling interests

4,237

3,490

Less: Comprehensive income attributable to noncontrolling interests

10

Comprehensive income attributable to Pfizer Inc.

4,236

3,480

(a)

Reclassified into Other (income)/deductions net and Cost of sales in the condensed consolidated statements of income. For additional information on amounts reclassified into Cost of sales, see Note 7E. Financial Instruments: Derivative Financial Instruments and Hedging Activities.

(b)

For additional information, see Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in 2018 in our 2018 Financial Report.

Amounts may not add due to rounding.

See Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(MILLIONS OF DOLLARS)

March 31,

2019

December 31,

2018

(Unaudited)

Assets

Cash and cash equivalents

1,937

1,139

Short-term investments

9,682

17,694

Trade accounts receivable, less allowance for doubtful accounts: 2019 $538; 2018 $541

9,599

8,025

Inventories

8,029

7,508

Current tax assets

3,598

3,374

Other current assets

2,567

2,461

Assets held for sale

9,877

9,725

Total current assets

45,290

49,926

Long-term investments

2,859

2,767

Property, plant and equipment, less accumulated depreciation: 2019 $16,158; 2018 $16,591

13,467

13,385

Identifiable intangible assets, less accumulated amortization

34,039

35,211

Goodwill

53,487

53,411

Noncurrent deferred tax assets and other noncurrent tax assets

1,946

1,924

Other noncurrent assets

4,333

2,799

Total assets

155,421

159,422

Liabilities and Equity

Short-term borrowings, including current portion of long-term debt: 2019 $4,471; 2018 $4,776

9,410

8,831

Trade accounts payable

4,156

4,674

Dividends payable

2,047

Income taxes payable

1,849

1,265

Accrued compensation and related items

1,797

2,397

Other current liabilities

10,276

10,753

Liabilities held for sale

1,935

1,890

Total current liabilities

29,423

31,858

Long-term debt

35,733

32,909

Pension benefit obligations, net

5,125

5,272

Postretirement benefit obligations, net

1,332

1,338

Noncurrent deferred tax liabilities

3,591

3,700

Other taxes payable

14,712

14,737

Other noncurrent liabilities

6,346

5,850

Total liabilities

96,263

95,664

Commitments and Contingencies

Preferred stock

19

19

Common stock

468

467

Additional paid-in capital

86,635

86,253

Treasury stock

(110,781

(101,610

Retained earnings

93,388

89,554

Accumulated other comprehensive loss

(10,923

(11,275

Total Pfizer Inc. shareholders equity

58,806

63,407

Equity attributable to noncontrolling interests

352

351

Total equity

59,158

63,758

Total liabilities and equity

155,421

159,422

Amounts may not add due to rounding.

See Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF EQUITY

PFIZER INC. SHAREHOLDERS

Preferred Stock

Common Stock

Treasury Stock

(MILLIONS, EXCEPT PREFERRED SHARES)

Shares

Stated Value

Shares

Par Value

Add l

Paid-In Capital

Shares

Cost

Retained Earnings

Accum. Other Comp.

Loss

Share-

holders Equity

Non-controlling interests

Total Equity

Balance, January 1, 2019

478

19

9,332

467

86,253

(3,615

(101,610

89,554

(11,275

63,407

351

63,758

Net income

3,884

3,884

3,889

Other comprehensive income/(loss), net of tax

353

353

(4

348

Cash dividends declared:

Common stock

(68

(68

(68

Preferred stock

Noncontrolling interests

Share-based payment transactions

26

383

(7

(306

78

78

Purchases of common stock

(180

(8,865

(8,865

(8,865

Preferred stock conversions and redemptions

(12

(1

(1

(1

Other(a)

19

19

19

Balance, March 31, 2019

466

19

9,358

468

86,635

(3,801

(110,781

93,388

(10,923

58,806

352

59,158

PFIZER INC. SHAREHOLDERS

Preferred Stock

Common Stock

Treasury Stock

(MILLIONS, EXCEPT PREFERRED SHARES)

Shares

Stated Value

Shares

Par Value

Add l

Paid-In Capital

Shares

Cost

Retained Earnings

Accum. Other Comp.

Loss

Share-

holders Equity

Non-controlling interests

Total Equity

Balance, January 1, 2018

524

21

9,275

464

84,278

(3,296

(89,425

85,291

(9,321

71,308

348

71,656

Net income

3,561

3,561

3,570

Other comprehensive income/(loss), net of tax

(81

(81

(80

Cash dividends declared:

Common stock

(65

(65

(65

Preferred stock

Noncontrolling interests

Share-based payment transactions

24

321

29

351

351

Purchases of common stock

(145

(6,063

(6,063

(6,063

Preferred stock conversions and redemptions

(11

(1

(1

(1

Other(b)

1,175

1,175

1,175

Balance, April 1, 2018

513

21

9,299

465

84,599

(3,437

(95,460

89,961

(9,402

70,184

358

70,541

(a)

Represents the cumulative effect of the adoption of a new accounting standard in the first quarter of 2019 for leases. For additional information, see Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards.

(b)

Represents the cumulative effect of the adoption of new accounting standards in the first quarter of 2018 for revenues, financial assets and liabilities, income tax accounting, and the reclassification of certain tax effects from Accumulated other comprehensive income. For additional information, see Notes to Consolidated Financial Statements Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in 2018 in Pfizer s 2018 Financial Report.

Amounts may not add due to rounding.

See Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

Three Months Ended

(MILLIONS OF DOLLARS)

March 31,

2019

April 1,

2018

Operating Activities

Net income before allocation to noncontrolling interests

3,889

3,570

Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:

Depreciation and amortization

1,545

1,567

Asset write-offs and impairments

155

TCJA impact(a)

(131

(68

Deferred taxes from continuing operations

(60

294

Share-based compensation expense

185

182

Benefit plan contributions in excess of expense

(151

(692

Other adjustments, net

(236

(161

Other changes in assets and liabilities, net of acquisitions and divestitures

(3,498

(2,715

Net cash provided by operating activities

1,698

1,983

Investing Activities

Purchases of property, plant and equipment

(460

(386

Purchases of short-term investments

(1,402

(913

Proceeds from redemptions/sales of short-term investments

3,601

6,463

Net proceeds from redemptions/sales of short-term investments with original maturities of three months or less

5,941

4,507

Purchases of long-term investments

(84

(605

Proceeds from redemptions/sales of long-term investments

44